Weight-Loss Injections Linked to Five Deaths in Scotland Amid Safety Probe
Edinburgh | Health regulators in Scotland have launched an urgent safety investigation after five deaths were officially linked to weight-loss injection treatments, sparking growing concerns over the safety of widely used drugs such as tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy).
According to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), 361 adverse incidents and five fatal cases have been reported since January 2024. The watchdog confirmed that three of the deceased were using the medication purely for weight loss, with one diabetic case and another under investigation.
Among the tragic cases is Susan McGowan, a 58-year-old NHS nurse from Airdrie, who died after just two injections of tirzepatide. Her death certificate cites pancreatitis, septic shock, and organ failure, with the use of tirzepatide listed as a contributory factor.
Black Market Products Raise Alarm
Officials are also warning the public about the growing black market for weight-loss drugs, with counterfeit or unlicensed versions of semaglutide and tirzepatide being sold online and through illicit suppliers. These versions may contain incorrect dosages, unapproved chemicals, or contaminated ingredients.
The MHRA has already seized hundreds of falsified pens, prompting a public health alert.
“The benefits of GLP-1 receptor agonists remain significant when used properly, but misuse or use of unauthorized versions poses serious risks to life,” said an MHRA spokesperson.
Government and Medical Response
Scottish health officials are calling for tighter regulations, including:
-
Mandatory follow-ups for all patients using GLP-1 drugs
-
New enforcement actions against unauthorized suppliers
-
A review of current prescribing and pharmacy practices
Doctors are urging patients to avoid obtaining these medications without medical supervision and to report any sudden abdominal pain, vomiting, or unusual symptoms immediately.
Investigation Ongoing
The MHRA and NHS Scotland have confirmed that full toxicology reports and pharmaceutical trace analyses are ongoing. No criminal charges have been announced yet, but sources say illegal online sales are now under scrutiny by law enforcement and health crime units.
Background: GLP-1 drugs, originally developed for type 2 diabetes, have become global bestsellers for weight management. They mimic gut hormones to suppress appetite and slow digestion—but can also carry risks including pancreatitis, gallbladder disease, and gastrointestinal complications.
Stay with InternationalNews.uk for updates on this developing story.
